Phase III Trial of Stage I Ovarian Cancer After Surgery

Inclusion Criteria:

1. Patients with a diagnosis of histopathologically epithelial ovarian cancer

2. FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) andIc(b)(all degree of differentiation and all histologic type)

3. Patients with a diagnosis of advanced stage by comprehensive staging or restaginglaparotomy.

4. Patients who received comprehensive staging surgery (basic surgical techniques (totalhysterectomy, bilateral salpingo-oophorectomy, and omentectomy) as well as peritonealcytology, multiple biopsies of the peritoneum ([Peritoneal biopsy] see details below),retroperitoneal lymph node dissection (see details below [Retroperitoneal lymph nodedissection]). However, for the following cases, it is eligible as a condition to record on theofficial document.

• Peritoneal biopsy: peritoneal metastasis is not recognized by macroscopic andpalpation in the stipulated site, and the case that biopsy has not beenperformed.

• Retroperitoneal lymph node dissection: the case that lymph nodes of thestipulated range has been dissected however the prescribed number has not beenreached.

5. Age: 20 or older

6. Performance status (PS):0-1

7. Case with initial therapy for postoperative primary lesion

8. Patient possible to receive the first study treatment within 8 weeks after thecomprehensive staging surgery

9. Reasonable organ function

10. Patient must have signed informed consent.

Exclusion Criteria:

1. FIGO Stages Ic(a), Ic(1) and Ic(2)

2. Patients containing sarcoma elements

3. Patients with any signs of interstitial pneumonia or pulmonary fibrosis by chestradiography and CT

4. Patients with serious complications

5. Patients with active infection

6. Patients with intestinal paralysis or intestinal obstruction

7. Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy

8. Patients with previous chemotherapy or radiation therapy

9. Patients with serious drug hypersensitivity

10. Patients with peripheral motor/sensory neuropathy [grade2,3,4 Common TerminologyCriteria for Adverse Events (CTCAE) 4.0]

11. Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenatedcastor oil

12. Patients with positive HBsAg. Patients with more than 2.1 log/copies ml based on fixedHepatitis B virus (HBV)-DNA who are positive with either antigen-positive Hepatitis B (HBs), anti-hepatitis B core antigen or anti-hepatitis B surface antigen.

13. Patients who are inappropriate to enter this study with any safety reasons, judged bythe treating physician